ESDS Software Solution Ltd ESDS

Summary

ESDS is a 20-year-old, profitable Indian cloud and managed-services provider — IaaS, Managed Services and SaaS across BFSI, government and enterprise customers, MeitY-empanelled as a Cloud Service Provider, and running its own "SWARAJ" suite of AI-ops, security and DevSecOps products — that IPO'd on 4 September 2026, roughly two weeks before this report's research date. The underlying business is real and growing: standalone revenue rose from ₹281 crore (FY24) to ₹357 crore (FY25) to an estimated ~₹472-481 crore (FY26, corroborated across two independent sources), with PAT climbing from ₹16 crore to ₹61 crore to ~₹121 crore over the same period and 94.9% FY26 revenue retention. CRISIL upgraded the company's rating to A-/Positive (long-term) and A2+ (short-term) on ~16-17 September 2026 — a genuine, independent, and essentially contemporaneous credit signal.

The headline catalyst is a USD 1.25 billion, five-year contract (with a two-year extension option) disclosed via a Choice Institutional Equities brokerage report (~7 September 2026) with a counterparty named "Sharon AI," covering roughly 8,208 NVIDIA B300 GPUs, targeted to go live in October 2026 with revenue recognition from Q3 FY27, against a ₹1,180 crore advance already received. Choice itself frames this contract as worth roughly 25x ESDS's FY26 revenue — and flags "customer concentration as AI revenue scales" among its own key risks. This research could not independently verify Sharon AI's identity, nationality or creditworthiness from a second source.

Since listing, the stock has moved in a way this report treats as a standalone risk factor independent of the underlying business: it opened at ₹757 (a 76% premium to the ₹429 issue price), was reported at various points over the following two weeks as running up to somewhere between 235% and 270% above the issue price, and has since been placed under Long-Term ASM Stage 1 surveillance, with BSE seeking a clarification on the "significant price movement" on 9 September 2026 (the company responded that no undisclosed information existed). At the 18 September 2026 close of ₹1,565, the stock already sits at or above the only confirmed brokerage target located in this research — Choice's own ₹1,550 — leaving essentially no headroom even under the house that likes the stock. Trailing P/E is reported anywhere from 157x to 302x depending on source and share-count basis, a ~2x dispersion that itself signals how unstable any multiple is only two weeks after listing.

Net: a SELL, driven by valuation and concentration risk layered on top of extreme post-listing volatility, not by a judgment that the core business is weak. ESDS's base cloud/managed-services franchise is profitable and growing at a reasonable clip; the price being asked for it, and for one large, unverified customer contract, is not.

• A USD 1.25 billion contract with cash already in hand. The Sharon AI deal (5-year term, 2-year extension option, ~8,208 NVIDIA B300 GPUs, infrastructure targeted for October 2026) came with a ₹1,180 crore advance already received per Choice Institutional Equities — real, disclosed cash, not just a signed letter of intent.
• A genuinely diversified, profitable core business underneath the AI headline. IaaS, Managed Services and SaaS revenue grew from ₹281cr (FY24) to ~₹481cr (FY26), with PAT growing faster than revenue (₹16cr to ~₹121cr) and 94.9% FY26 revenue retention.
• Deep, certified government and BFSI relationships. MeitY CSP empanelment, 724+ bank branches on its BFSI cloud, and ISO 27001/9001/27017/27018/27701/42001 plus CMMI Level 5 certification — a durable, less speculative base underneath the single large GPU contract.
• An independent, contemporaneous positive credit signal. CRISIL upgraded ESDS to A-/Positive (long-term) and A2+ (short-term) on ~16-17 September 2026, essentially concurrent with this report.
• The one confirmed sell-side view is constructive. Choice Institutional Equities initiated coverage with a Buy and a ₹1,550 target (~7 Sep 2026), valuing the stock on 18x FY28E EV/EBITDA (~31x forward P/E) — a materially lower multiple than the stock's current trailing P/E, which this report reads as the market itself signalling the current price has run ahead of the sell-side's own bull case.

• Single-customer concentration at an extreme scale. The Sharon AI contract represents roughly 25x FY26 revenue, per Choice's own report, which itself lists "customer concentration as AI revenue scales" among its key risks — and this research could not verify Sharon AI's identity, nationality, or creditworthiness from any second source.
• The stock already trades at or above its only confirmed brokerage target. CMP of ₹1,565 (18 Sep 2026) sits above Choice's ₹1,550 target — the sell-side's own published bull case offers essentially no further headroom from here.
• Extreme, possibly disorderly post-listing price action. Reported run-ups of 235-270% above the ₹429 issue price within roughly two weeks triggered Long-Term ASM Stage 1 surveillance and a BSE clarification request (9 Sep 2026) — a market-structure red flag independent of the underlying fundamentals.
• Trailing P/E is genuinely unstable. Reported figures range from 157x (groww.in) to 302x (screener.in) for the same stock on the same day, a ~2x dispersion driven by differing share-count and period bases only weeks after listing — this report treats neither figure as reliable in isolation.
• Board independence may fall short of the SEBI LODR threshold. As listed (Piyush Somani as Chairman & MD, Komal Somani as a further promoter-family whole-time director, two further executive directors, and three independent non-executive directors), independent directors are ~43% of a 7-member board — below the 50% threshold required for an executive-chaired company, unconfirmed against the latest corporate-governance report.
• A wide range of governance and disclosure items could not be verified at all in this research pass — the statutory auditor's identity, any litigation history, and related-party-transaction disclosures — an unusually large gap even for a company this newly public, because the DRHP itself was not directly accessible during this research.

• Sharon AI infrastructure launch (targeted October 2026) and the first quarter of revenue recognition (Q3 FY27).
• Independent confirmation of Sharon AI's identity and creditworthiness via an exchange filing — the single most important unresolved fact behind this company's entire AI thesis.
• Confirmation of current board composition and independent-director percentage against SEBI LODR's threshold for an executive-chaired company.
• Subject and outcome of the 12 September 2026 postal ballot.
• Whether Long-Term ASM Stage 1 surveillance is lifted, maintained, or escalated.

• Valuation risk (dominant). CMP already sits at or above the only confirmed brokerage target, on trailing multiples of 157x-302x with barely two weeks of trading history behind them.
• Concentration risk. A single, ~25x-revenue customer contract with an unverified counterparty.
• Governance-disclosure risk. Possible sub-50% independent board, unverified statutory auditor, and inaccessible litigation/RPT disclosures.
• Market-structure risk. ASM Stage 1 surveillance and extreme post-listing volatility, independent of underlying fundamentals.
• Execution risk on the October 2026 GPU-infrastructure go-live underpinning the entire Sharon AI revenue case.

IPO-stage, ~2 weeks of trading history — treat all multiples in this section as unstable. Screener.in's 302x trailing P/E implies a trailing EPS of only ~₹5.18, which appears to reflect an earnings base that predates full consolidation of FY26 results; groww.in's 157.75x is more consistent with the well-corroborated ~₹121cr FY2026 PAT on a post-IPO share count of ~12cr shares, implying trailing EPS of ~₹10.00. We use ₹10.00 as the more defensible trailing EPS below, but flag plainly that neither figure has more than two weeks of post-listing trading behind it, and CMP ÷ disclosed trailing P/E is therefore an illustration of how rich the current price is, not a precise forecast:

Base case rounded to ₹1,000. Even our bull-case scenario, at a 140x trailing multiple — still far above the ~31x forward P/E implied by Choice Institutional Equities' own ₹1,550 target (18x FY28E EV/EBITDA) — produces meaningful downside from the current ₹1,565, underscoring how far the current trading price has detached from even the most constructive sell-side view located in this research. Choice's ₹1,550 target (~7 Sep 2026), the only confirmed brokerage reference point found, already sits below CMP.

Source: screener.in and groww.in (18-20 Sep 2026), cross-checked against a Choice Institutional Equities brokerage report (via dsij.in, ~7 Sep 2026) and a Hindu BusinessLine DRHP-sourced review; FY26 revenue/PAT are corroborated between groww.in (₹481cr/₹121cr) and Hindu BusinessLine's DRHP figure (₹120.8cr PAT) but could not be independently confirmed against a full post-listing screener.in annual line item in this research pass.